Niagen Bioscience, Inc.

NCM: NAGE
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Niagen Bioscience, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get NAGE Z-Score →

About Niagen Bioscience, Inc.

Healthcare Biotechnology
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

📊 Fundamental Analysis

Niagen Bioscience, Inc. demonstrates a healthy profit margin of 13.4%.

The company recently reported 16.2% revenue growth, which is well above average for the Healthcare sector.

Return on Equity (ROE) is 28.3%, which exceeds the Healthcare sector average, reflecting efficient capital allocation.

At a current price of $4.50, NAGE currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $4.16 - $14.69).

💰 Valuation Insight

NAGE is valued broadly in line with the sector at a PE of 22.50. Analysts expect earnings growth, as indicated by a lower forward PE.

🏥 Financial Health

⚠️ Profit Margin Moderate
🔴 Debt/Equity Elevated
Revenue Growth Excellent
Return on Equity Excellent
🔴 Beta (Risk) High Volatility

Key Financials

Market Cap
$360.36M
Trailing P/E
22.50
Forward P/E
14.06
Beta (5Y)
2.23
52W High
$14.69
52W Low
$4.16
Avg Volume
1.19M
Day High
Day Low
Get NAGE Z-Score on Dashboard 🚀